A Novel OGR1 (GPR68) Inhibitor Attenuates Inflammation in Murine Models of Colitis

Abstract

This is the first report providing evidence that a pharmacological inhibition of OGR1 has a therapeutic effect in murine colitis models. Our data suggest that targeting proton-sensing OGR1 using specific small-molecule inhibitors may be a novel therapeutic approach for the treatment of IBD.